Research Synthesis: Carnosine Anti-Glycation

Abstract

This paper synthesizes carnosine anti glycation as an aging-related intervention across 38 included source papers and 1568 high-confidence extracted claims.

The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base.

Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

Introduction

The global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations.

The geroscience hypothesis reframes drug development by proposing that interventions targeting aging biology — rather than single disease endpoints — could yield multiplicative benefits across organ systems. In this framework, Carnosine anti glycation is of particular interest because its proposed mechanism of action — scavenging reactive carbonyl species to prevent advanced glycation end-product (AGE) formation — intersects with a pathway implicated in vascular stiffening, renal decline, neuropathy, and cartilage degradation. The logic of repurposing Carnosine anti glycation as an anti-aging agent rests on these observational associations and its favorable safety profile as a dietary supplement. However, whether intervening on the glycation pathway — as opposed to merely observing its correlates — can reverse or slow these trajectories is a fundamentally different empirical question.

Several unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints.

This synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete.

Background

The background evidence for carnosine anti glycation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Movahedian 2025, Ozdemir 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the frailty, safety and comorbidity and immune and inflammation outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes; and negative or adverse signals around the contextual adjacent evidence and cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct clinical signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-carnosine_anti_glycation-v06-DAILY-2026-05-31T07-31-55Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-31.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• carnosine anti glycation AND aging AND human
• carnosine anti glycation AND older adults
• carnosine anti glycation AND randomized controlled trial
• carnosine AND aging AND human
• carnosine AND older adults
• carnosine AND randomized controlled trial
• anti-glycation AND aging AND human
• anti-glycation AND older adults
• anti-glycation AND randomized controlled trial
• AGEs AND aging AND human

Eligibility criteria

• Sources whose primary content addresses carnosine anti glycation.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 171 records in the receipt-candidate union, 51 were classified as source candidates and 38 were admitted as traceable synthesis sources. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	171
Classified source candidates	51
No extractable claims	35
None-only claim binding	11
Partial/none-only claim binding	51
Partial-only candidates	17
Strict high-confidence sources	6
Admitted final sources	38

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=20; claims=657	null signal in 15/20 sources	16 indirect; 4 review	limited corpus depth in this outcome class
Cardiometabolic	n=6; claims=513	null signal in 4/6 sources	2 direct; 2 indirect; 2 review	limited corpus depth in this outcome class
Population / prevalence	n=3; claims=178	null signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=22	positive signal in 1/2 sources	2 indirect	limited corpus depth in this outcome class
Cognitive	n=1; claims=48	null signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Dosing and Pharmacokinetics	n=1; claims=7	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Frailty	n=1; claims=34	positive signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune	n=1; claims=35	null signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Mortality and Survival	n=1; claims=12	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Muscle Function	n=1; claims=37	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Safety and Comorbidity	n=1; claims=25	positive signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Cardiometabolic Outcomes

The synthesis examined six studies addressing carnosine and advanced glycation end-products (AGEs) in cardiometabolic contexts.

Quantitative findings across these studies present a mixed profile. Ozdemir 2025 found metabolic and hormonal improvements in the low-AGE diet group, with several endpoints reaching significance (P = 0.027, P = 0.001).

Mechanistically, carnosine's anti-glycation properties may attenuate AGE accumulation and downstream oxidative stress pathways relevant to cardiometabolic health. The clinical RCT by Movahedian 2025 provides direct evidence that AGE modulation via melatonin affects inflammation and oxidative stress markers. Ozdemir 2025's RCT data suggest that reducing dietary AGE intake can improve metabolic and hormonal profiles in PCOS patients. Observational data from Xue 2025 and Nevarez 2025 provide cross-sectional associations but cannot establish causality regarding AGE-mediated cardiometabolic pathways.

Within-corpus tensions emerge between studies reporting null or non-significant findings and those demonstrating significant cardiometabolic benefits. Ozdemir 2025 demonstrated significant metabolic improvements (P = 0.001) that contrast with the null findings from observational studies. These disagreements suggest that carnosine's cardiometabolic effects are context-dependent, with intervention type, population, and endpoint specificity moderating the observed effects.

Cognitive Outcomes

The corpus contains a single direct evidence source addressing cognitive outcomes in the context of anti-glycation interventions: a systematic umbrella review and meta-meta-analysis by Singh 2025. This review synthesized evidence across multiple domains, reporting that shorter intervention durations of 1 to 3 months and exergames (video games requiring physical movement) showed the largest effects on general cognition and memory. The study design was observational and review-level, with no enrolled clinical population specific to carnosine supplementation (Singh 2025).

This pattern of mixed significance underscores the context-dependent nature of cognitive outcomes: short-duration interventions and active gaming modalities appear efficacious, whereas other exercise forms or durations may not reach significance. The evidence does not directly evaluate carnosine's anti-glycation mechanisms in cognitive domains.

Mechanistically, the anti-glycation properties of carnosine may relate to cognitive outcomes through protection against advanced glycation end-product (AGE) accumulation in neural tissue, a pathway implicated in neurodegeneration. However, the sole available review (Singh 2025) does not address this mechanistic pathway directly; instead, it evaluates physical activity and exergaming interventions that may share downstream neuroprotective effects such as enhanced cerebral blood flow and neurotrophic factor expression. Preclinical data from the broader carnosine literature suggest glycation-inhibiting properties relevant to brain aging, but this mechanistic substrate is not yet grounded in human-RCT evidence specific to carnosine supplementation for cognition.

Within the corpus, a notable tension exists: the cognitive outcome class is populated solely by Singh 2025, which addresses exercise rather than carnosine directly, creating an indirect evidence gap. This heterogeneity parallels the broader thesis that the carnosine anti-aging case remains incomplete: mechanistic plausibility for anti-glycation benefits in cognition coexists with sparse or absent direct human-RCT evidence for carnosine supplementation. The boundary conditions for any cognitive benefit remain to be established through targeted interventional trials.

Contextual Adjacent Evidence Outcomes

The evidence base for advanced glycation end products (AGEs) as contextual biomarkers is derived entirely from observational cohort designs, with no interventional RCTs directly testing carnosine's anti-glycation effects within this corpus. Studies span diverse clinical populations including children, adults with type 2 diabetes, patients with aortic stenosis, exfoliation glaucoma, hypertrophic cardiomyopathy, endometriosis, and diabetic retinopathy. The indirectness of this evidence to carnosine itself is substantial, as most studies measured circulating or tissue AGE levels rather than investigating carnosine supplementation.

Quantitative findings across these cohorts consistently demonstrate that AGE levels are significantly elevated in disease states relative to controls. Selcuki 2026 demonstrated significantly elevated AGEs in endometriosis patients compared with controls (P < 0.001).

Mechanistically, AGE accumulation is proposed to contribute to tissue damage through cross-linking of structural proteins, activation of the receptor for AGEs (RAGE), and downstream NF-κB signaling. Nowotny 2015 outlined that the proteasomal system degrades more than 90% of oxidatively damaged proteins, a pathway potentially overwhelmed by AGE-modified substrates in diabetes. Chuntakaruk 2021 provided preclinical data showing that purple corn anthocyanins suppressed NF-κB and MAPK signaling in AGE-induced porcine cartilage degradation, suggesting a mechanistic avenue for anti-glycation interventions. Zhang 2025 reported that three months of intervention with Vaccinium myrtillus extract (600 mg/day) reduced CML levels, though CEL levels were not significantly changed. This mechanistic substrate underscores biological plausibility but does not directly address carnosine's efficacy.

Mechanistically, the null findings across these disparate clinical contexts—frailty, PCOS, and valve prolapse—suggest that glycation-related deficiency prevalence is not a primary driver of pathology in these conditions. These observational data provide indirect evidence that does not support a strong, uniform prevalence signal.

A minor tension within this outcome class is the variation in reported p-values. This pattern of mixed non-significance underscores the bounded, context-dependent nature of the evidence, where no single glycation-related deficiency emerges as a consistently prevalent biomarker across these studied conditions.

Dosing and Pharmacokinetics Outcomes

In a clinical observational cohort, the NEAT trial investigated carnosine supplementation in adults, examining cognitive performance metrics as a primary endpoint. The study design involved administration of carnosine with the primary focus on evaluating speed, accuracy, and efficiency as key cognitive outcomes. This trial provides foundational data on the pharmacokinetic and dose-response relationship of carnosine in human participants, establishing a framework for understanding its functional effects in a controlled setting.

Quantitative analysis from the observational cohort revealed a significant age-dependent response to carnosine supplementation. Specifically, scores for speed, accuracy, and efficiency were significantly higher for individuals aged 23-35 years than those in the older age groups, as illustrated in the study's figures. However, in the unadjusted model, the overall effect of supplementation did not reach statistical significance, indicating a context-dependent profile where benefits are concentrated in a younger demographic.

Mechanistically, the observed age-related divergence in cognitive outcomes may reflect differential bioavailability or cellular uptake of carnosine across the lifespan, a hypothesis supported by its role as a dipeptide with complex metabolism. Preclinical data suggest that carnosine's anti-glycation properties are modulated by tissue-specific carnosinase activity, which could vary with age. This mechanistic substrate provides a plausible explanation for the functional finding of enhanced efficacy in younger participants.

Within the corpus, the evidence for carnosine's dosing and pharmacokinetic profile presents a nuanced picture. The NEAT trial's findings of null overall unadjusted effects but significant benefits in a specific subgroup highlight a tension between generalized supplementation expectations and age-specific efficacy. This context-dependent outcome underscores that the boundary conditions for carnosine's cognitive benefits remain to be fully established, reinforcing the incomplete nature of the current evidence base.

Mechanistically, the association between elevated advanced glycation end products and mobility decline aligns with the proposed anti-glycation role of carnosine. Higher skin autofluorescence reflects cumulative glycation damage in structural proteins, a process that carnosine may attenuate through its nucleophilic carbonyl-scavenging properties. The functional endpoints measured—gait speed and sit-to-stand performance—directly reflect muscle and connective tissue integrity, which are vulnerable to glycation-mediated cross-linking. This observational evidence provides a plausible mechanistic bridge between carnosine's biochemical activities and clinically relevant frailty outcomes.

Immune and Inflammation Outcomes

The available evidence on carnosine's anti-glycation effects in the context of immune-inflammatory outcomes is derived exclusively from observational studies. Sukon 2024 conducted an observational cohort in adults with active immune-mediated ocular inflammatory diseases, assessing the association between skin autofluorescence (SAF) advanced glycation end product (AGE) levels and disease activity. Lee 2026 explored the anti-inflammatory potential of Aloe vera flower components in a skin inflammation model induced by glyoxal-derived AGEs (GO-AGEs). The directness of evidence from these studies is classified as indirect, as they do not evaluate exogenous carnosine supplementation directly but rather examine the broader relationship between AGE burden and inflammatory processes.

This finding suggests that lower glycation burden, as measured by SAF, correlates with a state of active inflammatory disease in this specific population. The study reported two p-values of P = 0.04 from its multivariate analysis. In contrast, the experimental work by Lee 2026, which investigated the mitigation of GO-AGE-induced skin inflammation by Aloe vera compounds, reported null findings for its primary endpoints, indicating no significant anti-inflammatory effect in that model. These exact p-values are detailed in the per-study evidence table.

Mechanistically, the hypothesis linking carnosine's anti-glycation properties to immune modulation posits that reducing AGE accumulation may attenuate the receptor for AGE (RAGE) signaling pathway, a key driver of sterile inflammation. The finding from Sukon 2024 (P = 0.04) provides indirect human observational support for the concept that AGE levels are dynamically associated with inflammatory disease activity. Preclinical data from Lee 2026 tested whether blocking AGE formation or action could reduce inflammation in a glyoxal-AGE skin model. The integration of these studies suggests that while the AGE-inflammatory axis is clinically relevant, the specific intervention point—whether via prevention (anti-glycation) or mitigation—is critical.

A notable within-corpus tension exists regarding the direction of the association between AGE levels and inflammation. By contrast, Lee 2026's null results in an induced AGE-inflammation model suggest that simply administering an anti-glycation agent did not reverse the inflammatory cascade. This disagreement highlights the complexity of the AGE-immune interaction and underscores that the relationship is likely context-dependent, varying with disease state, tissue, and timing of measurement.

The quantitative findings for the mortality and survival outcome class are characterized by null or near-null effects. This result points to a lack of a meaningful protective or harmful association between dAGEs consumption and the studied survival endpoint. The review, as a synthesis of observational data, provides effect estimates that are not derived from controlled interventions but from population-level associations, which are subject to confounding. Therefore, the observed HR of 0.99 should be interpreted within the context of methodological limitations inherent to observational cohort designs.

Mechanistically, the rationale for a survival benefit from reducing glycative stress via carnosine involves its known capacity to inhibit AGE formation and accumulate in long-lived tissues. However, the clinical evidence from this observational review does not translate this mechanistic plausibility into a clear mortality benefit. This disconnect highlights a common challenge in nutritional epidemiology, where biological activity demonstrated in preclinical or in vitro models does not consistently manifest as a significant effect in human observational studies. The review by Pascual-Morena (2025) thus underscores that the anti-glycation action of carnosine, while biochemically relevant, may not be a dominant determinant of cancer or overall survival at the dietary exposure levels studied.

Quantitative findings from this observational work revealed multiple statistically significant associations between glycation markers and biomechanical properties. These statistically significant relationships suggest a plausible mechanistic link between glycation processes and tissue biomechanics, though the cross-sectional design precludes causal inference.

Mechanistically, the observation that AGE levels correlate with corneal biomechanical properties aligns with established pathways whereby glycation cross-links alter tissue stiffness and elasticity. This human observational data provides a clinical correlate to preclinical evidence suggesting carnosine may inhibit AGE formation. However, the study did not measure muscle tissue directly, and the translation from corneal biomechanics to skeletal muscle function requires caution. The pathway from glycation inhibition to functional improvement remains theoretically plausible but empirically unvalidated in this specific context.

Quantitative findings from this cohort showed statistically significant improvements in the intervention arm. These results suggest a favorable modulation of surrogate markers in CCS patients, supporting a potential anti-glycation benefit in the context of existing cardiovascular disease.

Population / prevalence Outcomes

Within the corpus, substantial tensions exist regarding the consistency of AGE biomarker associations. Dahlen 2025 examined healthy elderly (HE) and frail elderly (FE) populations, assessing frailty and comorbidity status. Melamed 2025 conducted a systematic review and meta-analysis on mitral valve prolapse prevalence in general and hospital cohorts.

Quantitative findings from these cohorts consistently report null or non-significant associations for glycation-related deficiency prevalence. The exact p-values from Dahlen 2025's frailty analysis are available in Table 2.

Population / prevalence is retained as a separate Results slice (n=3; null signal in 3/3 sources; 2 indirect; no direct clinical anchor) and is not pooled into adjacent endpoint classes.

Frailty Outcomes

Frailty Outcomes. The observational cohort study by Park 2025 examined the relationship between advanced glycation end products, measured via skin autofluorescence, and mobility decline in a population of adults. The analysis structured participants into quartile groups based on skin autofluorescence values to compare physical function outcomes. Key endpoints included sit-to-stand test performance and gait speed, which are established mobility measures relevant to frailty assessment. The study reported highly significant associations across multiple comparisons, with p-values consistently below 0.001 for the primary functional measures.

Quantitative findings from Park 2025 demonstrate that the highest quartile (Q4) of skin autofluorescence exhibited a general decline in sit-to-stand performance and gait speed compared to lower quartiles. These effect sizes suggest a dose-response relationship between glycation burden and functional impairment. The consistency of statistical significance across multiple mobility markers strengthens the observational signal linking glycation to frailty-related outcomes.

By contrast, this evidence base is concentrated in a single observational cohort design, which cannot establish causality between glycation reduction and functional improvement. The Park 2025 findings describe an association between glycation burden and mobility decline but do not directly test carnosine supplementation. Whether carnosine intervention at doses achievable through dietary or supplemental means would reduce skin autofluorescence and thereby preserve mobility remains an open question. The signal is suggestive but bounded by the absence of interventional data specifically targeting carnosine's anti-glycation effects on frailty outcomes in this corpus.

Frailty remains a separate Results slice (n=1; claims=34; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Immune Outcomes

Immune Outcomes. The evidence base for immune-related outcomes of carnosine anti-glycation is derived from observational data and mechanistic reviews. The Razak 2025 protocol, which references prior human studies, notes that interventions with related compounds such as tocotrienol-rich fractions can improve antioxidant enzyme activities and glutathione levels in older women (Razak 2025). This study focuses on a population of older adults, for whom immune and oxidative stress pathways are particularly relevant. The directness of this evidence is classified as review-level, synthesizing previous findings rather than presenting new trial data (Razak 2025). No primary p-values or effect sizes are provided within the curated source for this protocol.

The mechanistic rationale links carnosine's anti-glycation properties to the modulation of oxidative stress, a key pathway in immune aging. Preclinical and human mechanistic studies suggest that glycation and the formation of advanced glycation end-products (AGEs) contribute to cellular dysfunction and inflammation. By inhibiting glycation, carnosine may theoretically support antioxidant defenses, akin to the reported effects of TRF on glutathione levels (Razak 2025). However, the human evidence directly testing this linkage for carnosine in immune outcomes remains sparse. The single available source points to a plausible biological pathway but does not provide quantitative clinical endpoints from a dedicated carnosine anti-glycation trial.

A key tension within this outcome class is the indirect nature of the available evidence. The supportive mechanistic pathway is grounded in studies of related antioxidant compounds, not carnosine itself (Razak 2025). There are no source-cited human randomized controlled trials that directly quantify carnosine's effect on immune markers or clinical immune outcomes in the context of anti-glycation. This creates a gap between the plausible biological mechanism and the required clinical validation. The current evidence profile is therefore incomplete, with positive signals for the underlying mechanism but a lack of direct human RCT data for the specific intervention.

Mortality and Survival Outcomes

Mortality and Survival Outcomes. The evidence base for carnosine and dietary advanced glycation end products (dAGEs) in relation to mortality and survival outcomes was examined through a systematic review and meta-analysis of observational cohort studies (Pascual-Morena 2025). This review synthesized data from multiple studies, but the overall analysis found that dAGEs intake was not associated with overall cancer risk. This evidence suggests that the relationship between dietary glycation load and mortality endpoints, including cancer-specific survival, is not robustly supported by current observational data. The population in this review was not a specific enrolled clinical cohort but represented aggregated data from existing epidemiological studies.

Within the corpus, the evidence for the mortality and survival outcome class presents a tension between mechanistic expectation and epidemiological observation. The single available source (Pascual-Morena 2025) provides a quantitative signal that is null, which stands in contrast to the broader theoretical framework where anti-glycation is posited to mitigate age-related decline and comorbidity risk. This tension is not resolved within this specific outcome class, as there are no counterbalancing human RCTs or longitudinal studies showing a significant survival effect. The finding reinforces the thesis that the carnosine anti-aging case is incomplete, with mixed or sparse human-RCT evidence, and that the boundary conditions for a mortality benefit remain to be established.

Muscle Function Outcomes

Muscle Function Outcomes. The evidence for carnosine's anti-glycation effects on muscle function is limited to a single observational cohort study in adults with glaucoma. Takagi 2026 examined the association between corneal biomechanical properties and fingertip-measured advanced glycation end products (AGEs) and carotenoids. The mean AGE score in this population was 0.42 ± 0.10 arbitrary units, while the mean carotenoid score was 338.5 ± 130.8 optical density units. The study design provides indirect evidence for the potential relevance of glycation to tissue biomechanics, though it did not directly assess carnosine supplementation.

The Takagi 2026 findings represent the entirety of direct evidence within this outcome class, creating a sparse evidence base for muscle function outcomes. While the significant associations between glycation markers and biomechanical properties provide mechanistic plausibility, the absence of randomized controlled trials examining carnosine supplementation limits the strength of conclusions. The boundary conditions for any anti-glycation effect on muscle function remain to be established, as the current evidence base consists solely of observational associations rather than intervention studies. This evidence profile is consistent with the broader synthesis indicating that mechanistic plausibility coexists with mixed or sparse human-RCT evidence across the carnosine literature.

Safety and Comorbidity Outcomes

Safety and Comorbidity Outcomes. One observational cohort study (Ursic 2026) evaluated the safety and comorbidity-related effects of carnosine-enriched chicken meat in a clinical population. The trial enrolled 38 participants with chronic coronary syndrome (CCS), randomizing them into a control group (N = 19) consuming regular chicken and an intervention group receiving carnosine-enriched chicken (Ursic 2026). The study assessed microvascular function and inflammatory markers as primary endpoints, reflecting the anti-glycation hypothesis relevant to cardiovascular comorbidity.

Mechanistically, the observed improvements in microvascular function are consistent with carnosine's purported role as an anti-glycation agent. Glycation products contribute to endothelial dysfunction and vascular stiffness in cardiovascular disease (Ursic 2026). Preclinical data suggest carnosine can inhibit advanced glycation end-product formation, which may underpin the clinical signal for improved microvascular reactivity and reduced inflammation in this human cohort.

By contrast, the evidence base for this outcome class is limited to a single indirect-evidence observational study, which constrains the strength of any conclusion. The positive findings from Ursic 2026 in adults with chronic coronary syndrome provide a promising signal, but the absence of large-scale randomized controlled trials in broader or healthier populations leaves the boundary conditions undefined. The overall synthesis indicates that while the safety and comorbidity profile appears favorable, this signal requires confirmation through more direct and robustly designed clinical RCTs.

Cross-Domain Synthesis

The most salient cross-domain tension in the carnosine anti-glycation evidence base is the divergence between observational biomarker data and clinical-endpoint RCTs. Multiple observational cohorts and cross-sectional studies consistently report that elevated advanced glycation end products (AGEs) are associated with worse cardiometabolic outcomes. This body of observational work establishes robust mechanistic plausibility: glycation stress appears to track with vascular and metabolic pathology. However, the direct clinical RCT evidence tells a different story. Movahedian 2025, examining melatonin's anti-glycation effects in peritoneal dialysis, yielded null primary outcomes. The boundary condition appears to be disease stage and intervention type: AGE-lowering dietary strategies in relatively metabolically intact populations may not produce detectable clinical benefit, whereas carnosine supplementation in already-diabetic cohorts may shift glycemic surrogates without yet demonstrating mortality or hospitalization reduction. Resolving this tension requires long-duration RCTs with hard clinical endpoints—mortality, cardiovascular events, renal failure—in populations with high baseline AGE burden, rather than reliance on short-term surrogate markers.

A second load-bearing tension exists between the cardiometabolic and frailty/physical-function outcome classes. Park 2025 provides strong observational evidence that higher skin autofluorescence (SAF) values—reflecting tissue AGE accumulation—are significantly associated with mobility decline, including reduced sit-to-stand performance and slower gait speed (P < 0.001 for comparisons across SAF quartile groups). This finding aligns with a broader geroscience model in which cross-linked proteins accumulate in connective tissue, reducing vascular compliance and muscle function over time. If AGE accumulation drives subclinical gait-speed decline at a rate exceeding the typical annual age-related loss of 0.05 m/s (Bohannon 1997), then anti-glycation interventions could theoretically slow functional aging. Yet the cardiometabolic RCT evidence does not support this extrapolation. Ozdemir 2025 and Movahedian 2025 both tested anti-glycation interventions and found null or mixed cardiometabolic results. Li 2025's meta-analysis found that carnosine supplementation reduced fasting blood glucose in diabetic populations, but physical function and frailty endpoints were not reported. The tension is that biomarker-level AGE accumulation appears to track with functional decline observationally, but no RCT has tested whether lowering AGEs via carnosine supplementation preserves gait speed, grip strength, or sit-to-stand performance in older adults. The boundary condition is likely population age and baseline functional status: the Park 2025 cohort comprised adults with measurable mobility decline, while the RCT populations were younger and metabolically different.

A third, underappreciated tension concerns the immune-inflammatory domain. This observation is counterintuitive: if AGEs drive pro-inflammatory signaling through the RAGE pathway, one would expect elevated AGEs during active inflammation, not reduced levels. In contrast, Lee 2026 investigated glyoxal-derived AGEs (GO-AGEs) in a skin inflammation model and found that AGEs directly induced inflammatory markers, with anti-inflammatory compounds attenuating this effect. These two findings—Sukon 2024's inverse association and Lee 2026's direct pro-inflammatory induction—appear contradictory. The likely resolution involves measurement site and disease context: Sukon 2024 measured skin autofluorescence (a cumulative tissue AGE proxy), while Lee 2026 measured circulating or experimentally applied AGEs. Tissue-bound AGEs may reflect long-term metabolic clearance rather than acute inflammatory burden; in active autoimmune flares, increased proteasomal degradation of glycated proteins (Nowotny 2015) could transiently lower measurable tissue AGEs even as systemic inflammation rises. The boundary condition is therefore temporal: acute inflammatory episodes may deplete tissue AGE stores through accelerated proteolysis, whereas chronic low-grade glycation stress accumulates in tissues over years and eventually amplifies inflammatory signaling. Ursic 2026 adds a relevant data point, showing that carnosine-enriched chicken meat improved microvascular function and anti-inflammatory phenotype in chronic coronary syndrome patients (P = 0.05 for microvascular improvement). This suggests that exogenous carnosine supplementation may shift the inflammatory balance in chronic disease, but it does not address the acute-phase paradox observed by Sukon 2024. Resolving this tension requires longitudinal studies that track both tissue AGE levels and inflammatory markers through disease flares and remissions, ideally in populations with autoimmune conditions where the RAGE-NF-κB axis is well-characterized.

Another cross-domain tension involves the relationship between dietary AGE restriction and clinical outcomes. Several observational and intervention studies support the premise that dietary AGE intake modulates circulating AGE levels and downstream pathology. Detopoulou 2024's systematic review of dietary AGE restriction RCTs in diabetes synthesizes this literature but reports unclear overall effect direction, suggesting that the clinical translation of dietary AGE reduction remains uncertain. The critical tension is between the dietary-AGE-restriction paradigm and the carnosine-supplementation paradigm. Dietary restriction targets exogenous AGE exposure, aiming to reduce the AGE pool through avoidance of processed and high-heat-cooked foods. Carnosine supplementation targets endogenous glycation, acting as a competitive scavenger of reactive carbonyl species before they modify proteins. These are mechanistically distinct strategies, and the sources suggest that neither has produced definitive hard-endpoint evidence. Li 2025's meta-analysis found that carnosine or beta-alanine supplementation reduced fasting blood glucose, but this is a surrogate marker, and as Ioannidis 2005 reminds us, surrogate associations do not guarantee hard-outcome validity. Evidence that would resolve this tension includes head-to-head RCTs comparing dietary AGE restriction with carnosine supplementation versus standard care, powered for hard clinical endpoints such as renal function decline, cardiovascular events, or mortality.

A fifth and perhaps most consequential tension for the anti-aging thesis is the disconnect between the breadth of AGE-associated pathology and the narrowness of intervention evidence. This breadth of association suggests that glycation is a fundamental biological process with pleiotropic disease consequences, consistent with the geroscience hypothesis that aging is driven by a small number of interconnected mechanisms. Yet the intervention evidence is strikingly narrow. The boundary condition is almost certainly the translation gap between associative epidemiology and causal intervention: AGE accumulation may be a marker of biological aging rather than a driver of it, much as HbA1c is a marker of glycemic exposure that correlates with complications but whose reduction does not always prevent them. Resolving this tension demands Mendelian randomization studies to test whether genetically determined AGE levels causally predict disease, and mechanistic RCTs that measure AGE reduction alongside hard clinical endpoints—not just biomarker shifts. Until such evidence exists, the anti-glycation anti-aging case remains what the picked thesis describes: incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence and unresolved boundary conditions.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 38 curated reference papers, the evidence base for carnosine anti glycation shows a context-dependent profile. Positive signals appear in: frailty, safety comorbidity. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces 205 non-orthogonal tensions across outcome classes — see Cross-Domain Synthesis. The carnosine anti glycation anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The carnosine anti glycation evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 2 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain.

Positive sources (Park 2025, Ursic 2026, Sukon 2024) are important, but they must be read alongside null sources (Movahedian 2025, Kabthymer 2024, Dahlen 2025) and negative sources (Kopytek 2025, Li 2025, Ozdemir 2025). This comparison keeps the discussion from converting selected favorable findings into a generalized anti-aging conclusion.

The practical implication is a calibrated research position. Carnosine Anti Glycation may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base.

The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the frailty, safety and comorbidity and immune and inflammation outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes or adverse results in the contextual adjacent evidence and cardiometabolic outcome classes. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival.

The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis can support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The interpretation calibrates confidence, clinical meaning, generalizability, and unresolved study-design needs. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Confidence calibration

The most cautious reading is that the evidence may support a bounded and context-dependent interpretation, but it might not generalize across populations, endpoints, doses, or follow-up windows without additional direct tests. The pattern suggests biological plausibility where it is consistent with the retained sources, yet it appears qualified by uncertainty, limited directness, and preliminary evidence in several domains. A cautious interpretive stance is therefore warranted: what remains to be established is whether the observed signals travel cleanly from mechanism or adjacent evidence into the target clinical or organizational outcome.

Resolution criteria: The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus of 38 references is dominated by observational cohort designs and mechanistic or review-type indirect evidence, with only two RCTs directly testing clinical or functional endpoints (Movahedian 2025; Ursic 2026). Both of these direct trials enrolled narrow populations — peritoneal dialysis patients and chronic coronary syndrome patients, respectively — limiting generalizability to broader healthy or at-risk adult populations. Notably, no long-term mortality RCT evaluating carnosine supplementation appears in this corpus, creating a critical gap for any anti-aging or survival claim. Similarly, no large-scale multi-site RCT assessing hard cardiometabolic endpoints (e.g., myocardial infarction, stroke) was identified. The absence of these canonical evidence types means the synthesis cannot move beyond hypothesis-generating conclusions regarding carnosine's capacity to reduce glycation-driven disease burden.

Several outcome domains in the synthesis rest on single-study evidence, precluding internal replication. For example, the positive signal linking advanced glycation end products to frailty and mobility decline is drawn exclusively from Park 2025, which reported associations between skin autofluorescence and functional measures such as gait speed — a metric where the clinically meaningful change threshold is approximately 0.1 m/s (Perera 2006). Similarly, cognitive outcomes tied to carnosine supplementation appear only in OToole 2025, which found age-stratified effects in the NEAT trial without corroborating RCTs in this corpus. The association between AGEs and endometriosis is supported solely by Selcuki 2026, and the link to uveitis activity only by Sukon 2024. Without replication across independent cohorts, these single-trial signals remain provisional and vulnerable to confounding, selection bias, or measurement artifact.

Population specificity poses a substantial external-validity constraint. Furthermore, most included trials enrolled predominantly European or Middle Eastern participants, and no study in this corpus specifically examined carnosine anti-glycation effects in East Asian, African, or Indigenous populations where dietary AGE exposure patterns may differ. Gender representation was uneven as well — several studies focused exclusively on women, such as the PCOS investigation (Yurt 2025) and endometriosis cohort (Selcuki 2026), while others enrolled only adults with comorbid conditions unlikely to represent the general aging population.

The endpoint scope of this corpus is narrowly focused on biomarker and surrogate outcomes rather than hard clinical endpoints. The majority of included studies measured circulating AGE levels, skin autofluorescence, or inflammatory markers — surrogate endpoints whose capacity to predict hard clinical outcomes remains uncertain (Ioannidis 2005). No study in this corpus reported all-cause mortality, incident cardiovascular events, or cancer incidence as primary endpoints in a carnosine supplementation trial. The existing evidence for cancer risk and mortality from dietary AGEs was limited to systematic review summaries with largely null associations and wide confidence intervals (Pascual-Morena 2025). Additionally, mechanistic plausibility — carnosine's capacity to scavenge reactive carbonyl species and inhibit AGE crosslinking — is well-established in preclinical models, yet the corpus contains no RCT bridging this mechanism to a confirmed reduction in glycation-mediated tissue damage in humans. This mechanism-to-clinic gap means that even where the biochemistry is compelling, the human evidence cannot yet validate anti-glycation as a therapeutic strategy.

Conclusion

The final interpretation is deliberately tiered. Carnosine Anti Glycation has a biologically plausible geroscience rationale and selected clinical signals, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence.

The strongest interpretation is that positive signals in the frailty, safety and comorbidity and immune and inflammation outcome classes coexist with null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. That profile supports further targeted research and careful hypothesis refinement, not unqualified clinical or public-health claims.

The current corpus may support carnosine anti glycation as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. The safer translation path is a registered trial that specifies the endpoint layer in advance, pairs dosing with monitoring for metabolic and immune safety, and reports null or adverse signals with the same visibility as favorable results.

Future work should prioritize studies that connect mechanistic studies (the retained evidence base) to direct clinical outcomes represented by Movahedian 2025, Ozdemir 2025. Until that bridge is stronger, carnosine anti glycation remains a promising but bounded geroscience case whose most useful contribution is to define the next trial rather than to justify current clinical adoption.

The decisive unresolved question is not whether the intervention can move selected biomarkers or pathway markers, but whether those changes improve durable human function without offsetting harm, adherence failure, or loss in another clinically relevant domain. That question should set the bar for future claims, clinical translation, future study design, and any public recommendation.

What This Synthesis Adds

This synthesis maps 38 included sources on Carnosine anti glycation across 11 outcome classes and 205 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 38 curated reference papers, the evidence base for Carnosine anti glycation shows a context-dependent profile. Positive signals appear in: frailty, safety comorbidity. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Carnosine anti glycation anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Prior reviews in the corpus (Detopoulou 2024) emphasize convergent signals on Carnosine anti glycation. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cognitive	0	1	null	direct clinical gap
frailty	0	1	positive	direct clinical gap
muscle function	0	1	null	direct clinical gap
immune	0	1	null	direct clinical gap
cardiometabolic	2	4	negative, null	replication gap
contextual adjacent evidence	0	20	negative, null, unclear	direct clinical gap
immune and inflammation	0	2	null, positive	direct clinical gap
deficiency prevalence	0	3	null	direct clinical gap
dosing and pharmacokinetics	0	1	null	direct clinical gap
mortality and survival	0	1	unclear	direct clinical gap
safety and comorbidity	0	1	positive	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cognitive: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P2	frailty: direct clinical gap	0 direct and 1 indirect source; direction profile: positive
P3	muscle function: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P4	immune: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P5	cardiometabolic: replication gap	2 direct and 4 indirect sources; direction profile: negative, null

Next-Study Design Recommendation

The next high-yield study for Carnosine anti glycation should target the cognitive evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.

Structured Evidence Tables

The following tables present the structured evidence summary referenced throughout this paper. Numbers live in the tables; prose references them. Tables 1-3 cover included studies, per-study endpoint evidence, and cross-domain tensions; Table 4 is a supplemental design-level evidence weighting heuristic; Table 5 surfaces the underlying per-paper numeric index.

Table 1: Included Studies

Citation	Design	Tier	N	Population	Endpoint	Direction	Directness	Trial ID	Representative p-value	n claims
Movahedian 2025	RCT (clinical)	A1	—	adults	cardiometabolic	null	direct	—	P = 0.001	212
Kopytek 2025	Observational	B2	—	adults	contextual other	negative	indirect	—	P < 0.0001	157
Kabthymer 2024	Observational	B2	—	—	cardiometabolic	null	review	—	P = 0.00	95
Li 2025	Observational	B2	—	type 2 diabetes patients	cardiometabolic	negative	review	—	P < 0.00001	92
Dahlen 2025	Observational	B2	—	adults	deficiency prevalence	null	indirect	—	P < 0.001	62
Ozdemir 2025	RCT (clinical)	A1	—	adults	cardiometabolic	negative	direct	—	P = 0.001	58
Melamed 2025	Observational	B2	—	—	deficiency prevalence	null	review	—	P = 0.81	58
Yurt 2025	Observational	B2	—	adults	deficiency prevalence	null	indirect	—	P = 0.002	58
Hauser 2024	Observational	B2	—	adults	contextual other	negative	indirect	—	P = 0.001	53
Wellens 2025	Observational	B2	—	adults	contextual other	null	review	—	P = 0.0001	52
Varoniukaite 2025	Observational	B2	—	adults	contextual other	negative	indirect	—	P = 0.007	52
Selcuki 2026	Observational	B2	—	adults	contextual other	null	indirect	—	P < 0.001	52
Alharbi 2026	Observational	B2	—	type 2 diabetes patients	contextual other	negative	indirect	—	P = 0.015	51
Steenbeke 2022	Observational	B2	—	adults	contextual other	null	indirect	—	P < 0.0001	49
Singh 2025	Observational	B2	—	—	cognitive	null	review	—	P < 0.01	48
Xue 2025	Observational	B2	—	adults	cardiometabolic	null	indirect	—	P < 0.01	41
Astorino 2026	Observational	B2	—	adults	contextual other	null	indirect	—	—	38
Takagi 2026	Observational	B2	—	adults	muscle function	null	indirect	—	P < 0.0001	37
Tanito 2025	Observational	B2	—	adults	contextual other	null	indirect	—	P < 0.0001	35
Razak 2025	Observational	B2	—	older adults	immune	null	review	—	—	35
Park 2025	Observational	B2	—	adults	frailty	positive	indirect	—	P < 0.001	34
Mishra 2025	Observational	B2	—	adults	contextual other	null	indirect	—	P < 0.001	34
Ursic 2026	Observational	B2	—	adults	safety comorbidity	positive	indirect	—	P = 0.03	25
Li 2025b	Observational	B2	—	adults	contextual other	null	indirect	—	P < 0.001	23
Sukon 2024	Observational	B2	—	adults	immune inflammation	positive	indirect	—	P = 0.04	17
Detopoulou 2024	Review / meta-analysis	B1	—	type 2 diabetes patients	contextual other	unclear	review	—	—	15
Nevarez 2025	Observational	B2	—	type 2 diabetes patients	cardiometabolic	null	indirect	—	P = 0.012	15
Zhao 2025	Observational	B2	—	adults	contextual other	null	review	—	—	13
Pascual-Morena 2025	Observational	B2	—	—	mortality survival	unclear	review	—	—	12
Kataoka 2025	Observational	B2	—	adults	contextual other	null	indirect	—	—	8
OToole 2025	Observational	B2	—	adults	dosing pharmacokinetics	null	indirect	—	—	7
Zhang 2025	Observational	B2	—	adults	contextual other	null	indirect	—	—	7
Salmen 2025	Observational	B2	—	—	contextual other	null	review	—	—	5
Lee 2026	Observational	B2	—	adults	immune inflammation	null	indirect	—	—	5
Babtan 2026	Observational	B2	—	adults	contextual other	null	indirect	—	P = 0.016	5
Chuntakaruk 2021	Observational	B2	—	adults	contextual other	null	indirect	—	—	5
Nowotny 2015	Observational	B2	—	type 2 diabetes patients	contextual other	null	indirect	—	—	2
Luevano-Contreras 2010	Observational	B2	—	adults	contextual other	null	indirect	—	—	1

Table 2: Per-Study Endpoint Evidence

Endpoint	Study	p/CI	Direction	Directness	Tier	Interpretation
cardiometabolic	Movahedian 2025	P = 0.04	significant statistic	direct	A1	significant statistic; source-level direction remains null
cardiometabolic	Movahedian 2025	P = 0.001	significant statistic	direct	A1	significant statistic; source-level direction remains null
cardiometabolic	Movahedian 2025	P = 0.04	significant statistic	direct	A1	significant statistic; source-level direction remains null
cardiometabolic	Movahedian 2025	P = 0.03	significant statistic	direct	A1	significant statistic; source-level direction remains null
cardiometabolic	Movahedian 2025	P = 0.02	significant statistic	direct	A1	significant statistic; source-level direction remains null
cardiometabolic	Movahedian 2025	P = 0.03	significant statistic	direct	A1	significant statistic; source-level direction remains null
contextual other	Kopytek 2025	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Kopytek 2025	P > 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Kopytek 2025	P = 0.009	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Kopytek 2025	P > 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Kopytek 2025	P < 0.0001	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Kopytek 2025	P < 0.0001	negative summary	indirect	B2	reported statistic; source summary remains negative
cardiometabolic	Kabthymer 2024	P = 0.94	null summary	review	B2	reported statistic; source summary remains null
cardiometabolic	Kabthymer 2024	P = 0.00	significant statistic	review	B2	significant statistic; source-level direction remains null
cardiometabolic	Kabthymer 2024	P = 0.023	significant statistic	review	B2	significant statistic; source-level direction remains null
cardiometabolic	Kabthymer 2024	P = 0.57	null summary	review	B2	reported statistic; source summary remains null
cardiometabolic	Kabthymer 2024	P < 0.05	significant statistic	review	B2	significant statistic; source-level direction remains null
cardiometabolic	Kabthymer 2024	P = 0.05	null summary	review	B2	reported statistic; source summary remains null
cardiometabolic	Li 2025	P < 0.00001	negative summary	review	B2	reported statistic; source summary remains negative
cardiometabolic	Li 2025	P = 0.003	negative summary	review	B2	reported statistic; source summary remains negative
cardiometabolic	Li 2025	P < 0.00001	negative summary	review	B2	reported statistic; source summary remains negative
cardiometabolic	Li 2025	P = 0.003	negative summary	review	B2	reported statistic; source summary remains negative
cardiometabolic	Li 2025	P = 0.28	negative summary	review	B2	reported statistic; source summary remains negative
cardiometabolic	Li 2025	P = 0.66	negative summary	review	B2	reported statistic; source summary remains negative
deficiency prevalence	Dahlen 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Dahlen 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Dahlen 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Dahlen 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Dahlen 2025	P < 0.05	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Dahlen 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Ozdemir 2025	P = 0.183	negative summary	direct	A1	reported statistic; source summary remains negative
cardiometabolic	Ozdemir 2025	P = 0.027	negative summary	direct	A1	reported statistic; source summary remains negative
cardiometabolic	Ozdemir 2025	P = 0.364	negative summary	direct	A1	reported statistic; source summary remains negative
cardiometabolic	Ozdemir 2025	P = 0.001	negative summary	direct	A1	reported statistic; source summary remains negative
cardiometabolic	Ozdemir 2025	P = 0.001	negative summary	direct	A1	reported statistic; source summary remains negative
cardiometabolic	Ozdemir 2025	P = 0.001	negative summary	direct	A1	reported statistic; source summary remains negative
deficiency prevalence	Melamed 2025	P = 0.81	null summary	review	B2	reported statistic; source summary remains null
deficiency prevalence	Yurt 2025	P = 0.035	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Yurt 2025	P = 0.002	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Yurt 2025	P > 0.05	null summary	indirect	B2	reported statistic; source summary remains null
deficiency prevalence	Yurt 2025	P = 0.009	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Yurt 2025	P = 0.035	significant statistic	indirect	B2	significant statistic; source-level direction remains null
deficiency prevalence	Yurt 2025	P > 0.05	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Hauser 2024	P = 0.022	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Hauser 2024	P = 0.027	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Hauser 2024	P = 0.001	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Hauser 2024	P = 0.010	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Hauser 2024	P = 0.004	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Hauser 2024	P < 0.001	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Wellens 2025	P = 0.0001	significant statistic	review	B2	significant statistic; source-level direction remains null
contextual other	Wellens 2025	P = 0.001	significant statistic	review	B2	significant statistic; source-level direction remains null
contextual other	Wellens 2025	P = 0.004	significant statistic	review	B2	significant statistic; source-level direction remains null
contextual other	Wellens 2025	P = 0.05	null summary	review	B2	reported statistic; source summary remains null
contextual other	Wellens 2025	P = 0.0001	significant statistic	review	B2	significant statistic; source-level direction remains null
contextual other	Wellens 2025	P = 0.001	significant statistic	review	B2	significant statistic; source-level direction remains null
contextual other	Varoniukaite 2025	P = 0.386	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Varoniukaite 2025	P = 0.007	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Varoniukaite 2025	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Varoniukaite 2025	P = 0.008	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Varoniukaite 2025	P = 0.814	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Varoniukaite 2025	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Selcuki 2026	P = 0.007	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Selcuki 2026	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Selcuki 2026	P = 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Selcuki 2026	P = 0.011	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Selcuki 2026	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Selcuki 2026	P = 0.413	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Alharbi 2026	P = 0.015	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Alharbi 2026	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Alharbi 2026	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Alharbi 2026	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Alharbi 2026	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Alharbi 2026	P < 0.05	negative summary	indirect	B2	reported statistic; source summary remains negative
contextual other	Steenbeke 2022	P = 0.004	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Steenbeke 2022	P = 0.019	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Steenbeke 2022	P = 0.030	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Steenbeke 2022	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Steenbeke 2022	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Steenbeke 2022	P < 0.019	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cognitive	Singh 2025	P < 0.01	significant statistic	review	B2	significant statistic; source-level direction remains null
cognitive	Singh 2025	P < 0.01	significant statistic	review	B2	significant statistic; source-level direction remains null
cognitive	Singh 2025	P < 0.01	significant statistic	review	B2	significant statistic; source-level direction remains null
cognitive	Singh 2025	P = 0.13	null summary	review	B2	reported statistic; source summary remains null
cognitive	Singh 2025	P < 0.01	significant statistic	review	B2	significant statistic; source-level direction remains null
cognitive	Singh 2025	P = 0.04	significant statistic	review	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P < 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P < 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P < 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P < 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P < 0.01	significant statistic	indirect	B2	significant statistic; source-level direction remains null
cardiometabolic	Xue 2025	P > 0.05	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Astorino 2026	—	null	indirect	B2	no significant effect on contextual other
muscle function	Takagi 2026	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
muscle function	Takagi 2026	P = 0.015	significant statistic	indirect	B2	significant statistic; source-level direction remains null
muscle function	Takagi 2026	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
muscle function	Takagi 2026	P = 0.012	significant statistic	indirect	B2	significant statistic; source-level direction remains null
muscle function	Takagi 2026	P = 0.012	significant statistic	indirect	B2	significant statistic; source-level direction remains null
muscle function	Takagi 2026	P = 0.004	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P = 0.009	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P = 0.003	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P = 0.002	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P = 0.004	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Tanito 2025	P < 0.0001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
immune	Razak 2025	—	null	review	B2	no significant effect on immune
frailty	Park 2025	P < 0.001	positive summary	indirect	B2	reported statistic; source summary remains positive
frailty	Park 2025	P < 0.001	positive summary	indirect	B2	reported statistic; source summary remains positive
frailty	Park 2025	P < 0.001	positive summary	indirect	B2	reported statistic; source summary remains positive
frailty	Park 2025	P < 0.001	positive summary	indirect	B2	reported statistic; source summary remains positive
frailty	Park 2025	P = 0.006	positive summary	indirect	B2	reported statistic; source summary remains positive
frailty	Park 2025	P = 0.002	positive summary	indirect	B2	reported statistic; source summary remains positive
contextual other	Mishra 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Mishra 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Mishra 2025	P = 0.8	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Mishra 2025	P = 0.4	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Mishra 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Mishra 2025	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
safety comorbidity	Ursic 2026	P = 0.05	positive summary	indirect	B2	reported statistic; source summary remains positive
safety comorbidity	Ursic 2026	P = 0.03	positive summary	indirect	B2	reported statistic; source summary remains positive
safety comorbidity	Ursic 2026	P = 0.05	positive summary	indirect	B2	reported statistic; source summary remains positive
safety comorbidity	Ursic 2026	P = 0.04	positive summary	indirect	B2	reported statistic; source summary remains positive
safety comorbidity	Ursic 2026	P = 0.04	positive summary	indirect	B2	reported statistic; source summary remains positive
contextual other	Li 2025b	P = 0.025	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Li 2025b	P = 0.028	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Li 2025b	P = 0.007	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Li 2025b	P = 0.028	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Li 2025b	P < 0.001	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Li 2025b	P = 0.028	significant statistic	indirect	B2	significant statistic; source-level direction remains null
immune inflammation	Sukon 2024	P = 0.04	positive summary	indirect	B2	reported statistic; source summary remains positive
immune inflammation	Sukon 2024	P = 0.04	positive summary	indirect	B2	reported statistic; source summary remains positive
contextual other	Detopoulou 2024	—	unclear	review	B1	unclear effect on contextual other
cardiometabolic	Nevarez 2025	P = 0.396	null summary	indirect	B2	reported statistic; source summary remains null
cardiometabolic	Nevarez 2025	P = 0.012	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Zhao 2025	—	null	review	B2	no significant effect on contextual other
mortality survival	Pascual-Morena 2025	—	unclear	review	B2	unclear effect on mortality survival
contextual other	Kataoka 2025	—	null	indirect	B2	no significant effect on contextual other
dosing pharmacokinetics	OToole 2025	—	null	indirect	B2	no significant effect on dosing pharmacokinetics
contextual other	Zhang 2025	—	null	indirect	B2	no significant effect on contextual other
contextual other	Salmen 2025	—	null	review	B2	no significant effect on contextual other
immune inflammation	Lee 2026	—	null	indirect	B2	no significant effect on immune inflammation
contextual other	Babtan 2026	P = 0.016	significant statistic	indirect	B2	significant statistic; source-level direction remains null
contextual other	Babtan 2026	P = 0.112	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Babtan 2026	P = 0.192	null summary	indirect	B2	reported statistic; source summary remains null
contextual other	Chuntakaruk 2021	—	null	indirect	B2	no significant effect on contextual other
contextual other	Nowotny 2015	—	null	indirect	B2	no significant effect on contextual other
contextual other	Luevano-Contreras 2010	—	null	indirect	B2	no significant effect on contextual other

Table 3: Cross-Domain Tensions

Tension kind	Severity	source A	source B	Outcome class	Summary	Practical implication
null vs positive	3	Sukon 2024	Lee 2026	immune inflammation	Sukon 2024 (positive) vs Lee 2026 (null) on immune inflammation	null vs positive (notable)
null vs positive	3	Hauser 2024	Zhao 2025	contextual other	Hauser 2024 (negative) vs Zhao 2025 (null) on contextual other	null vs positive (notable)
agreement	1	Hauser 2024	Kopytek 2025	contextual other	Hauser 2024 (negative) vs Kopytek 2025 (negative) on contextual other	agreement (minor)
null vs positive	3	Hauser 2024	Zhang 2025	contextual other	Hauser 2024 (negative) vs Zhang 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Tanito 2025	contextual other	Hauser 2024 (negative) vs Tanito 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Wellens 2025	contextual other	Hauser 2024 (negative) vs Wellens 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Mishra 2025	contextual other	Hauser 2024 (negative) vs Mishra 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Li 2025b	contextual other	Hauser 2024 (negative) vs Li 2025b (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Salmen 2025	contextual other	Hauser 2024 (negative) vs Salmen 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Kataoka 2025	contextual other	Hauser 2024 (negative) vs Kataoka 2025 (null) on contextual other	null vs positive (notable)
agreement	1	Hauser 2024	Varoniukaite 2025	contextual other	Hauser 2024 (negative) vs Varoniukaite 2025 (negative) on contextual other	agreement (minor)
agreement	1	Hauser 2024	Alharbi 2026	contextual other	Hauser 2024 (negative) vs Alharbi 2026 (negative) on contextual other	agreement (minor)
null vs positive	3	Hauser 2024	Selcuki 2026	contextual other	Hauser 2024 (negative) vs Selcuki 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Babtan 2026	contextual other	Hauser 2024 (negative) vs Babtan 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Astorino 2026	contextual other	Hauser 2024 (negative) vs Astorino 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Luevano-Contreras 2010	contextual other	Hauser 2024 (negative) vs Luevano-Contreras 2010 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Nowotny 2015	contextual other	Hauser 2024 (negative) vs Nowotny 2015 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Chuntakaruk 2021	contextual other	Hauser 2024 (negative) vs Chuntakaruk 2021 (null) on contextual other	null vs positive (notable)
null vs positive	3	Hauser 2024	Steenbeke 2022	contextual other	Hauser 2024 (negative) vs Steenbeke 2022 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Zhao 2025	contextual other	Detopoulou 2024 (unclear) vs Zhao 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Zhang 2025	contextual other	Detopoulou 2024 (unclear) vs Zhang 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Tanito 2025	contextual other	Detopoulou 2024 (unclear) vs Tanito 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Wellens 2025	contextual other	Detopoulou 2024 (unclear) vs Wellens 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Mishra 2025	contextual other	Detopoulou 2024 (unclear) vs Mishra 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Li 2025b	contextual other	Detopoulou 2024 (unclear) vs Li 2025b (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Salmen 2025	contextual other	Detopoulou 2024 (unclear) vs Salmen 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Kataoka 2025	contextual other	Detopoulou 2024 (unclear) vs Kataoka 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Selcuki 2026	contextual other	Detopoulou 2024 (unclear) vs Selcuki 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Babtan 2026	contextual other	Detopoulou 2024 (unclear) vs Babtan 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Astorino 2026	contextual other	Detopoulou 2024 (unclear) vs Astorino 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Luevano-Contreras 2010	contextual other	Detopoulou 2024 (unclear) vs Luevano-Contreras 2010 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Nowotny 2015	contextual other	Detopoulou 2024 (unclear) vs Nowotny 2015 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Chuntakaruk 2021	contextual other	Detopoulou 2024 (unclear) vs Chuntakaruk 2021 (null) on contextual other	null vs positive (notable)
null vs positive	3	Detopoulou 2024	Steenbeke 2022	contextual other	Detopoulou 2024 (unclear) vs Steenbeke 2022 (null) on contextual other	null vs positive (notable)
null vs positive	3	Zhao 2025	Kopytek 2025	contextual other	Zhao 2025 (null) vs Kopytek 2025 (negative) on contextual other	null vs positive (notable)
agreement	1	Zhao 2025	Zhang 2025	contextual other	Zhao 2025 (null) vs Zhang 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Tanito 2025	contextual other	Zhao 2025 (null) vs Tanito 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Wellens 2025	contextual other	Zhao 2025 (null) vs Wellens 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Mishra 2025	contextual other	Zhao 2025 (null) vs Mishra 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Li 2025b	contextual other	Zhao 2025 (null) vs Li 2025b (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Salmen 2025	contextual other	Zhao 2025 (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Kataoka 2025	contextual other	Zhao 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Zhao 2025	Varoniukaite 2025	contextual other	Zhao 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Zhao 2025	Alharbi 2026	contextual other	Zhao 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Zhao 2025	Selcuki 2026	contextual other	Zhao 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Babtan 2026	contextual other	Zhao 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Astorino 2026	contextual other	Zhao 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Luevano-Contreras 2010	contextual other	Zhao 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Nowotny 2015	contextual other	Zhao 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Chuntakaruk 2021	contextual other	Zhao 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Zhao 2025	Steenbeke 2022	contextual other	Zhao 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
null vs positive	3	Xue 2025	Ozdemir 2025	cardiometabolic	Xue 2025 (null) vs Ozdemir 2025 (negative) on cardiometabolic	null vs positive (notable)
agreement	1	Xue 2025	Kabthymer 2024	cardiometabolic	Xue 2025 (null) vs Kabthymer 2024 (null) on cardiometabolic	agreement (minor)
null vs positive	3	Xue 2025	Li 2025	cardiometabolic	Xue 2025 (null) vs Li 2025 (negative) on cardiometabolic	null vs positive (notable)
agreement	1	Xue 2025	Nevarez 2025	cardiometabolic	Xue 2025 (null) vs Nevarez 2025 (null) on cardiometabolic	agreement (minor)
agreement	1	Xue 2025	Movahedian 2025	cardiometabolic	Xue 2025 (null) vs Movahedian 2025 (null) on cardiometabolic	agreement (minor)
null vs positive	3	Kopytek 2025	Zhang 2025	contextual other	Kopytek 2025 (negative) vs Zhang 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Tanito 2025	contextual other	Kopytek 2025 (negative) vs Tanito 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Wellens 2025	contextual other	Kopytek 2025 (negative) vs Wellens 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Mishra 2025	contextual other	Kopytek 2025 (negative) vs Mishra 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Li 2025b	contextual other	Kopytek 2025 (negative) vs Li 2025b (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Salmen 2025	contextual other	Kopytek 2025 (negative) vs Salmen 2025 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Kataoka 2025	contextual other	Kopytek 2025 (negative) vs Kataoka 2025 (null) on contextual other	null vs positive (notable)
agreement	1	Kopytek 2025	Varoniukaite 2025	contextual other	Kopytek 2025 (negative) vs Varoniukaite 2025 (negative) on contextual other	agreement (minor)
agreement	1	Kopytek 2025	Alharbi 2026	contextual other	Kopytek 2025 (negative) vs Alharbi 2026 (negative) on contextual other	agreement (minor)
null vs positive	3	Kopytek 2025	Selcuki 2026	contextual other	Kopytek 2025 (negative) vs Selcuki 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Babtan 2026	contextual other	Kopytek 2025 (negative) vs Babtan 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Astorino 2026	contextual other	Kopytek 2025 (negative) vs Astorino 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Luevano-Contreras 2010	contextual other	Kopytek 2025 (negative) vs Luevano-Contreras 2010 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Nowotny 2015	contextual other	Kopytek 2025 (negative) vs Nowotny 2015 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Chuntakaruk 2021	contextual other	Kopytek 2025 (negative) vs Chuntakaruk 2021 (null) on contextual other	null vs positive (notable)
null vs positive	3	Kopytek 2025	Steenbeke 2022	contextual other	Kopytek 2025 (negative) vs Steenbeke 2022 (null) on contextual other	null vs positive (notable)
null vs positive	3	Ozdemir 2025	Kabthymer 2024	cardiometabolic	Ozdemir 2025 (negative) vs Kabthymer 2024 (null) on cardiometabolic	null vs positive (notable)
agreement	1	Ozdemir 2025	Li 2025	cardiometabolic	Ozdemir 2025 (negative) vs Li 2025 (negative) on cardiometabolic	agreement (minor)
null vs positive	3	Ozdemir 2025	Nevarez 2025	cardiometabolic	Ozdemir 2025 (negative) vs Nevarez 2025 (null) on cardiometabolic	null vs positive (notable)
null vs positive	3	Ozdemir 2025	Movahedian 2025	cardiometabolic	Ozdemir 2025 (negative) vs Movahedian 2025 (null) on cardiometabolic	null vs positive (notable)
null vs positive	3	Kabthymer 2024	Li 2025	cardiometabolic	Kabthymer 2024 (null) vs Li 2025 (negative) on cardiometabolic	null vs positive (notable)
agreement	1	Kabthymer 2024	Nevarez 2025	cardiometabolic	Kabthymer 2024 (null) vs Nevarez 2025 (null) on cardiometabolic	agreement (minor)
agreement	1	Kabthymer 2024	Movahedian 2025	cardiometabolic	Kabthymer 2024 (null) vs Movahedian 2025 (null) on cardiometabolic	agreement (minor)
agreement	1	Zhang 2025	Tanito 2025	contextual other	Zhang 2025 (null) vs Tanito 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Wellens 2025	contextual other	Zhang 2025 (null) vs Wellens 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Mishra 2025	contextual other	Zhang 2025 (null) vs Mishra 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Li 2025b	contextual other	Zhang 2025 (null) vs Li 2025b (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Salmen 2025	contextual other	Zhang 2025 (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Kataoka 2025	contextual other	Zhang 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Zhang 2025	Varoniukaite 2025	contextual other	Zhang 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Zhang 2025	Alharbi 2026	contextual other	Zhang 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Zhang 2025	Selcuki 2026	contextual other	Zhang 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Babtan 2026	contextual other	Zhang 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Astorino 2026	contextual other	Zhang 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Luevano-Contreras 2010	contextual other	Zhang 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Nowotny 2015	contextual other	Zhang 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Chuntakaruk 2021	contextual other	Zhang 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Zhang 2025	Steenbeke 2022	contextual other	Zhang 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Wellens 2025	contextual other	Tanito 2025 (null) vs Wellens 2025 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Mishra 2025	contextual other	Tanito 2025 (null) vs Mishra 2025 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Li 2025b	contextual other	Tanito 2025 (null) vs Li 2025b (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Salmen 2025	contextual other	Tanito 2025 (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Kataoka 2025	contextual other	Tanito 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Tanito 2025	Varoniukaite 2025	contextual other	Tanito 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Tanito 2025	Alharbi 2026	contextual other	Tanito 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Tanito 2025	Selcuki 2026	contextual other	Tanito 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Babtan 2026	contextual other	Tanito 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Astorino 2026	contextual other	Tanito 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Luevano-Contreras 2010	contextual other	Tanito 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Nowotny 2015	contextual other	Tanito 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Chuntakaruk 2021	contextual other	Tanito 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Tanito 2025	Steenbeke 2022	contextual other	Tanito 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Mishra 2025	contextual other	Wellens 2025 (null) vs Mishra 2025 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Li 2025b	contextual other	Wellens 2025 (null) vs Li 2025b (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Salmen 2025	contextual other	Wellens 2025 (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Kataoka 2025	contextual other	Wellens 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Wellens 2025	Varoniukaite 2025	contextual other	Wellens 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Wellens 2025	Alharbi 2026	contextual other	Wellens 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Wellens 2025	Selcuki 2026	contextual other	Wellens 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Babtan 2026	contextual other	Wellens 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Astorino 2026	contextual other	Wellens 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Luevano-Contreras 2010	contextual other	Wellens 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Nowotny 2015	contextual other	Wellens 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Chuntakaruk 2021	contextual other	Wellens 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Wellens 2025	Steenbeke 2022	contextual other	Wellens 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Li 2025b	contextual other	Mishra 2025 (null) vs Li 2025b (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Salmen 2025	contextual other	Mishra 2025 (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Kataoka 2025	contextual other	Mishra 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Mishra 2025	Varoniukaite 2025	contextual other	Mishra 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Mishra 2025	Alharbi 2026	contextual other	Mishra 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Mishra 2025	Selcuki 2026	contextual other	Mishra 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Babtan 2026	contextual other	Mishra 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Astorino 2026	contextual other	Mishra 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Luevano-Contreras 2010	contextual other	Mishra 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Nowotny 2015	contextual other	Mishra 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Chuntakaruk 2021	contextual other	Mishra 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Mishra 2025	Steenbeke 2022	contextual other	Mishra 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Salmen 2025	contextual other	Li 2025b (null) vs Salmen 2025 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Kataoka 2025	contextual other	Li 2025b (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Li 2025b	Varoniukaite 2025	contextual other	Li 2025b (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Li 2025b	Alharbi 2026	contextual other	Li 2025b (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Li 2025b	Selcuki 2026	contextual other	Li 2025b (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Babtan 2026	contextual other	Li 2025b (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Astorino 2026	contextual other	Li 2025b (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Luevano-Contreras 2010	contextual other	Li 2025b (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Nowotny 2015	contextual other	Li 2025b (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Chuntakaruk 2021	contextual other	Li 2025b (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Li 2025b	Steenbeke 2022	contextual other	Li 2025b (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Kataoka 2025	contextual other	Salmen 2025 (null) vs Kataoka 2025 (null) on contextual other	agreement (minor)
null vs positive	3	Salmen 2025	Varoniukaite 2025	contextual other	Salmen 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Salmen 2025	Alharbi 2026	contextual other	Salmen 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Salmen 2025	Selcuki 2026	contextual other	Salmen 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Babtan 2026	contextual other	Salmen 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Astorino 2026	contextual other	Salmen 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Luevano-Contreras 2010	contextual other	Salmen 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Nowotny 2015	contextual other	Salmen 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Chuntakaruk 2021	contextual other	Salmen 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Salmen 2025	Steenbeke 2022	contextual other	Salmen 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Melamed 2025	Yurt 2025	deficiency prevalence	Melamed 2025 (null) vs Yurt 2025 (null) on deficiency prevalence	agreement (minor)
agreement	1	Melamed 2025	Dahlen 2025	deficiency prevalence	Melamed 2025 (null) vs Dahlen 2025 (null) on deficiency prevalence	agreement (minor)
agreement	1	Yurt 2025	Dahlen 2025	deficiency prevalence	Yurt 2025 (null) vs Dahlen 2025 (null) on deficiency prevalence	agreement (minor)
null vs positive	3	Li 2025	Nevarez 2025	cardiometabolic	Li 2025 (negative) vs Nevarez 2025 (null) on cardiometabolic	null vs positive (notable)
null vs positive	3	Li 2025	Movahedian 2025	cardiometabolic	Li 2025 (negative) vs Movahedian 2025 (null) on cardiometabolic	null vs positive (notable)
agreement	1	Nevarez 2025	Movahedian 2025	cardiometabolic	Nevarez 2025 (null) vs Movahedian 2025 (null) on cardiometabolic	agreement (minor)
null vs positive	3	Kataoka 2025	Varoniukaite 2025	contextual other	Kataoka 2025 (null) vs Varoniukaite 2025 (negative) on contextual other	null vs positive (notable)
null vs positive	3	Kataoka 2025	Alharbi 2026	contextual other	Kataoka 2025 (null) vs Alharbi 2026 (negative) on contextual other	null vs positive (notable)
agreement	1	Kataoka 2025	Selcuki 2026	contextual other	Kataoka 2025 (null) vs Selcuki 2026 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Babtan 2026	contextual other	Kataoka 2025 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Astorino 2026	contextual other	Kataoka 2025 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Luevano-Contreras 2010	contextual other	Kataoka 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Nowotny 2015	contextual other	Kataoka 2025 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Chuntakaruk 2021	contextual other	Kataoka 2025 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Kataoka 2025	Steenbeke 2022	contextual other	Kataoka 2025 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Varoniukaite 2025	Alharbi 2026	contextual other	Varoniukaite 2025 (negative) vs Alharbi 2026 (negative) on contextual other	agreement (minor)
null vs positive	3	Varoniukaite 2025	Selcuki 2026	contextual other	Varoniukaite 2025 (negative) vs Selcuki 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Babtan 2026	contextual other	Varoniukaite 2025 (negative) vs Babtan 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Astorino 2026	contextual other	Varoniukaite 2025 (negative) vs Astorino 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Luevano-Contreras 2010	contextual other	Varoniukaite 2025 (negative) vs Luevano-Contreras 2010 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Nowotny 2015	contextual other	Varoniukaite 2025 (negative) vs Nowotny 2015 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Chuntakaruk 2021	contextual other	Varoniukaite 2025 (negative) vs Chuntakaruk 2021 (null) on contextual other	null vs positive (notable)
null vs positive	3	Varoniukaite 2025	Steenbeke 2022	contextual other	Varoniukaite 2025 (negative) vs Steenbeke 2022 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Selcuki 2026	contextual other	Alharbi 2026 (negative) vs Selcuki 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Babtan 2026	contextual other	Alharbi 2026 (negative) vs Babtan 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Astorino 2026	contextual other	Alharbi 2026 (negative) vs Astorino 2026 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Luevano-Contreras 2010	contextual other	Alharbi 2026 (negative) vs Luevano-Contreras 2010 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Nowotny 2015	contextual other	Alharbi 2026 (negative) vs Nowotny 2015 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Chuntakaruk 2021	contextual other	Alharbi 2026 (negative) vs Chuntakaruk 2021 (null) on contextual other	null vs positive (notable)
null vs positive	3	Alharbi 2026	Steenbeke 2022	contextual other	Alharbi 2026 (negative) vs Steenbeke 2022 (null) on contextual other	null vs positive (notable)
agreement	1	Selcuki 2026	Babtan 2026	contextual other	Selcuki 2026 (null) vs Babtan 2026 (null) on contextual other	agreement (minor)
agreement	1	Selcuki 2026	Astorino 2026	contextual other	Selcuki 2026 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Selcuki 2026	Luevano-Contreras 2010	contextual other	Selcuki 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Selcuki 2026	Nowotny 2015	contextual other	Selcuki 2026 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Selcuki 2026	Chuntakaruk 2021	contextual other	Selcuki 2026 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Selcuki 2026	Steenbeke 2022	contextual other	Selcuki 2026 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Babtan 2026	Astorino 2026	contextual other	Babtan 2026 (null) vs Astorino 2026 (null) on contextual other	agreement (minor)
agreement	1	Babtan 2026	Luevano-Contreras 2010	contextual other	Babtan 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Babtan 2026	Nowotny 2015	contextual other	Babtan 2026 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Babtan 2026	Chuntakaruk 2021	contextual other	Babtan 2026 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Babtan 2026	Steenbeke 2022	contextual other	Babtan 2026 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Astorino 2026	Luevano-Contreras 2010	contextual other	Astorino 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other	agreement (minor)
agreement	1	Astorino 2026	Nowotny 2015	contextual other	Astorino 2026 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Astorino 2026	Chuntakaruk 2021	contextual other	Astorino 2026 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Astorino 2026	Steenbeke 2022	contextual other	Astorino 2026 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Luevano-Contreras 2010	Nowotny 2015	contextual other	Luevano-Contreras 2010 (null) vs Nowotny 2015 (null) on contextual other	agreement (minor)
agreement	1	Luevano-Contreras 2010	Chuntakaruk 2021	contextual other	Luevano-Contreras 2010 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Luevano-Contreras 2010	Steenbeke 2022	contextual other	Luevano-Contreras 2010 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Nowotny 2015	Chuntakaruk 2021	contextual other	Nowotny 2015 (null) vs Chuntakaruk 2021 (null) on contextual other	agreement (minor)
agreement	1	Nowotny 2015	Steenbeke 2022	contextual other	Nowotny 2015 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)
agreement	1	Chuntakaruk 2021	Steenbeke 2022	contextual other	Chuntakaruk 2021 (null) vs Steenbeke 2022 (null) on contextual other	agreement (minor)

Table 4 (supplemental): Design-Level Evidence Weighting Heuristic

Per-domain grades are derived from each study's evidence tier (A1/A2/B1/B2/C1/C2) — they capture design-level limitations, NOT a formal per-paper risk-of-bias assessment from the source text. Domains follow design-family categories for randomized, observational, animal, and systematic-review evidence; n/a indicates the domain is not meaningful for that design (e.g. blinding for an observational cohort). The Weight in synthesis column is the qualitative weighting the synthesis applies to each source — derived from tier × directness × overall RoB.

Citation	Tier	Tool	Allocation	Blinding	Attrition	Outcome measurement	Reporting	Confounding control	Generalizability	Overall RoB	Weight in synthesis	Effect direction notes
Movahedian 2025	A1	Cochrane RoB-2	low	low	moderate	low	low	low	moderate	low	load-bearing (direct clinical RCT)	primary endpoint did not reach significance
Kopytek 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	negative effect — see Tables 1/2
Kabthymer 2024	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Li 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	negative effect — see Tables 1/2
Dahlen 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Ozdemir 2025	A1	Cochrane RoB-2	low	low	moderate	low	low	low	moderate	low	load-bearing (direct clinical RCT)	negative effect — see Tables 1/2
Melamed 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Yurt 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Hauser 2024	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	negative effect — see Tables 1/2
Wellens 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Varoniukaite 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	negative effect — see Tables 1/2
Selcuki 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Alharbi 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	negative effect — see Tables 1/2
Steenbeke 2022	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Singh 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Xue 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Astorino 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Takagi 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Tanito 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Razak 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Park 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	positive effect — see Tables 1/2
Mishra 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Ursic 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	positive effect — see Tables 1/2
Li 2025b	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Sukon 2024	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	positive effect — see Tables 1/2
Detopoulou 2024	B1	AMSTAR-2 (review)	unclear	unclear	unclear	unclear	moderate	moderate	moderate	unclear	supporting (synthesis evidence)	signed claims without significance signal
Nevarez 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Zhao 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Pascual-Morena 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	signed claims without significance signal
Kataoka 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
OToole 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Zhang 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Salmen 2025	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Lee 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Babtan 2026	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Chuntakaruk 2021	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Nowotny 2015	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance
Luevano-Contreras 2010	B2	ROBINS-I	n/a	n/a	moderate	moderate	moderate	high	moderate	moderate	contextual (observational signal)	primary endpoint did not reach significance

Table 5 (supplemental): Per-Paper Numeric Index

Top-N quantitative claims per paper — the underlying corpus numerics that power Q2 trace and Q9 density. One row per (paper × claim) tuple, prioritised by claim type (p-value > percentage > ratio > unit-value).

Citation	Section	Type	Value	Units
Movahedian 2025	results	p-value	P = 0.04	—
Movahedian 2025	results	p-value	P = 0.03	—
Ozdemir 2025	abstract	p-value	P = 0.027	—
Ozdemir 2025	discussion	unit value	2 months	months
Ozdemir 2025	results	p-value	P < 0.005	—
Varoniukaite 2025	results	p-value	P = 0.206	—
Varoniukaite 2025	results	p-value	P = 0.005	—
Varoniukaite 2025	results	p-value	P = 0.310	—
Alharbi 2026	results	p-value	P < 0.001	—
Alharbi 2026	results	odds ratio	OR: 2.16	—
Alharbi 2026	results	confidence interval	95% CI: 1.06-4.09	95%CI
Ursic 2026	discussion	unit value	250 mg	mg
Ursic 2026	discussion	unit value	16 weeks	weeks
Ursic 2026	discussion	unit value	250 mg/kg/day	mg/kg/day
Ursic 2026	discussion	unit value	1000 mg/kg/day	mg/kg/day
Ursic 2026	discussion	unit value	1 month	month
Detopoulou 2024	discussion	percentage	50%	%

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: ADA 2024, Cruz-Jentoft 2019.

References

• Movahedian 2025. Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial. Scientific Reports, 2025. DOI: 10.1038/s41598-025-20792-2. PMID: 41125682.
• Kopytek 2025. Dysglycaemia is associated with the pattern of valvular calcification in micro-computed tomography analysis: an observational study in patients with severe aortic stenosis. Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02691-y. PMID: 40114166.
• Kabthymer 2024. Carnosine/histidine-containing dipeptide supplementation improves depression and quality of life: systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2024. DOI: 10.1093/nutrit/nuae021. PMID: 38545720.
• Li 2025. Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-02016-w. PMID: 40999397.
• Dahlen 2025. Fatigue and Vitamin D Status in Frail Elderly with and without Cancer, and Healthy Controls of Different Ages: Results from the IMAGE Study. Gerontology, 2025. DOI: 10.1159/000548451. PMID: 40952957.
• Ozdemir 2025. Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial. Reproductive Sciences, 2025. DOI: 10.1007/s43032-025-01808-8. PMID: 39953370.
• Melamed 2025. Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis. European Heart Journal. Quality of Care & Clinical Outcomes, 2025. DOI: 10.1093/ehjqcco/qcaf016. PMID: 40156585.
• Yurt 2025. Are Dietary and Serum Advanced Glycation End Products (AGEs) Potential Contributors to Inflammation in Women with Polycystic Ovary Syndrome?. Journal of Clinical Medicine, 2025. DOI: 10.3390/jcm14165803. PMID: 40869631.
• Hauser 2024. Subcutaneous advanced glycation end products, cardiovascular risk factors and vascular health during childhood development in a Swiss population. Frontiers in Physiology, 2024. DOI: 10.3389/fphys.2024.1371618. PMID: 39100277.
• Wellens 2025. Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects. Cell Reports Medicine, 2025. DOI: 10.1016/j.xcrm.2025.102091. PMID: 40280130.
• Varoniukaite 2025. Association of Advanced Glycation End Products with Diabetic Retinopathy Severity in Lithuanian Patients. Medicina, 2025. DOI: 10.3390/medicina61111956. PMID: 41303793.
• Selcuki 2026. Systemic Oxidative Stress Markers in Endometriosis: Elevated Advanced Glycation End Products and Sestrin 2 in Women with Ovarian Endometrioma. Biomedicines, 2026. DOI: 10.3390/biomedicines14020405.
• Alharbi 2026. Dietary advanced glycation end products (AGEs) and type 2 diabetes (T2D): a case-control study. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1737974. PMID: 41717025.
• Steenbeke 2022. Dietary Advanced Glycation End Products in an Elderly Population with Diabetic Nephropathy: An Exploratory Investigation. Nutrients, 2022. DOI: 10.3390/nu14091818. PMID: 35565786.
• Singh 2025. Effectiveness of exercise for improving cognition, memory and executive function: a systematic umbrella review and meta-meta-analysis. British Journal of Sports Medicine, 2025. DOI: 10.1136/bjsports-2024-108589. PMID: 40049759.
• Xue 2025. The relationship between advanced glycation end products, metabolic metrics, HbA 1c, and diabetic nephropathy. Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1468737. PMID: 40123890.
• Astorino 2026. The effect of low volume sprint interval training on cardiorespiratory fitness: study protocol for a definitive randomized controlled trial. Trials, 2026. DOI: 10.1186/s13063-026-09647-x. PMID: 41872855.
• Takagi 2026. Association of Corneal Biomechanical Properties with Fingertip-Measured Advanced Glycation End Products and Carotenoids in Glaucoma Patients. Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15020783. PMID: 41598720.
• Tanito 2025. Accelerated Biological Aging in Exfoliation Glaucoma Assessed by Fundus-Derived Predicted Age and Advanced Glycation End Products. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26104725. PMID: 40429867.
• Razak 2025. Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols, 2025. DOI: 10.2196/73039. PMID: 40986853.
• Park 2025. Advanced Glycation End Products and Mobility Decline: A Novel Perspective on Aging. Healthcare, 2025. DOI: 10.3390/healthcare13060613. PMID: 40150465.
• Mishra 2025. Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy. Indian Journal of Ophthalmology, 2025. DOI: 10.4103/IJO.IJO_2115_24. PMID: 40243083.
• Ursic 2026. Carnosine-Enriched Chicken Meat Improves Microvascular Function and Anti-Inflammatory Phenotype in Patients with Chronic Coronary Syndrome. Nutrients, 2026. DOI: 10.3390/nu18060928. PMID: 41901102.
• Li 2025b. The role of advanced glycation end products (AGEs) and the receptor for AGEs (RAGE) in hypertrophic obstructive cardiomyopathy. PLOS One, 2025. DOI: 10.1371/journal.pone.0328032. PMID: 40705819.
• Sukon 2024. Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases. International Ophthalmology, 2024. DOI: 10.1007/s10792-024-02980-7. PMID: 38329659.
• Detopoulou 2024. Dietary Restriction of Advanced Glycation End-Products (AGEs) in Patients with Diabetes: A Systematic Review of Randomized Controlled Trials. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms252111407. PMID: 39518960.
• Nevarez 2025. SAT-577 Assessing Advanced Glycation End-products (AGEs) in Type 1 Diabetes: Contributions of Serum, Dietary, and Skin AGEs. Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.1108.
• Zhao 2025. Exploration of brain imaging biomarkers in subthreshold depression patients across different ages: an ALE meta-analysis based on MRI studies. BMC Psychiatry, 2025. DOI: 10.1186/s12888-025-06495-y. PMID: 40033236.
• Pascual-Morena 2025. Association of Dietary Advanced Glycation End Products with Overall and Site-Specific Cancer Risk and Mortality: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17101638. PMID: 40431378.
• Kataoka 2025. Current Developments in Analytical Methods for Advanced Glycation End Products in Foods. Molecules, 2025. DOI: 10.3390/molecules30204095. PMID: 41157111.
• OToole 2025. Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial. Neurotherapeutics, 2025. DOI: 10.1016/j.neurot.2025.e00541. PMID: 39919936.
• Zhang 2025. Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants, 2025. DOI: 10.3390/antiox14040492. PMID: 40298887.
• Salmen 2025. Could Skin Autofluorescence Be a Useful Biomarker in Systemic Lupus Erythematosus? A Systematic Review. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26146934. PMID: 40725181.
• Lee 2026. Exploring the Anti-Inflammatory Effects of Aloe vera Flower (AVF) and Its Active Ingredients in a Skin Inflammation Model Induced by Glyoxal-Derived Advanced Glycation End Products (GO-AGEs). Pharmaceuticals, 2026. DOI: 10.3390/ph19010121. PMID: 41599719.
• Babtan 2026. Correlation Between Advanced Glycation End Products and Ultrasonographic Measurements of Cervico-Facial Skin Tissue. Diagnostics, 2026. DOI: 10.3390/diagnostics16081206. PMID: 42072831.
• Chuntakaruk 2021. Chondroprotective effects of purple corn anthocyanins on advanced glycation end products induction through suppression of NF-κB and MAPK signaling. Scientific Reports, 2021. DOI: 10.1038/s41598-021-81384-4. PMID: 33479339.
• Nowotny 2015. Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. Biomolecules, 2015. DOI: 10.3390/biom5010194. PMID: 25786107.
• Luevano-Contreras 2010. Dietary Advanced Glycation End Products and Aging. Nutrients, 2010. DOI: 10.3390/nu2121247. PMID: 22254007.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.